Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis

References

• Younossi ZM, Stepanova M, Younossi Y, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut 2020 Mar;69(3):564–568.
   PubMed Web of Science ®Google Scholar
• Setiawan VW, Stram DO, Porcel J, et al. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort. Hepatology 2016 Dec;64(6):1969–1977.
   PubMed Web of Science ®Google Scholar
• Noureddin M, Vipani A, Bresee C, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol. 2018 Nov;113(11):1649–1659.
   PubMed Web of Science ®Google Scholar
• Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015 Apr;62(1):S47–64.
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Adams LA, Canbay A, et al. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2014 Mar;59(3):1174–1197.
   PubMed Web of Science ®Google Scholar
• Lindenmeyer CC, McCullough AJ. The natural history of nonalcoholic fatty liver disease-an evolving view. Clin Liver Dis. 2018 Feb;22(1):11–21.
   PubMed Web of Science ®Google Scholar
• Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015 Aug;149(2):389–97 e10.
   PubMed Web of Science ®Google Scholar
• Povsic M, Oliver L, Jiandani NR, et al. A structured literature review of interventions used in the management of nonalcoholic steatohepatitis (NASH). Pharmacol Res Perspect. 2019 Jun;7(3):e00485.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Loomba R, Anstee QM, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology 2018 Jul;68(1):349–360.
   PubMed Web of Science ®Google Scholar
• Kim D, Kim WR, Kim HJ, et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013 Apr;57(4):1357–1365.
   PubMed Web of Science ®Google Scholar
• Noureddin N, Schattenberg JM, Alkhouri N, et al. Noninvasive testing using magnetic resonance imaging techniques as outcomes in nonalcoholic steatohepatitis clinical trials: how full is the glass? Hepatol Commun. 2020 Feb;4(2):141–144.
   PubMed Web of Science ®Google Scholar
• Piazzolla VA, Mangia A. Noninvasive diagnosis of NAFLD and NASH. Cells 2020 Apr 17;9(4):4.
   Web of Science ®Google Scholar
• Rinella ME, Noureddin M. STELLAR 3 and STELLAR 4: lessons from the fall of Icarus. J Hepatol. 2020 Jul;73(1):9–11.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Goodman Z, Jabbar A, et al. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. J Hepatol. 2020 May;72(5):816–827
   PubMedGoogle Scholar
• Garcia-Tsao G, Bosch J, Kayali Z, et al. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. J Hepatol. 2020 May;72(5):885–895.
   PubMed Web of Science ®Google Scholar
• Meer EG, McLaughlin M, Matthews L, et al. Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial. Liver Int. 2016 Dec;36(12):1783–1792.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Wong VW, Okanoue T, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol. 2020 Jul;73(1):26–39.
   PubMed Web of Science ®Google Scholar
• Glass O, Filozof C, Noureddin M, et al. Standardisation of diet and exercise in clinical trials of NAFLD-NASH: recommendations from the Liver Forum. J Hepatol. 2020 Sep;73(3):680–693.
   PubMed Web of Science ®Google Scholar
• Diaz-Alvarez L, Ortega E. The many roles of galectin-3, a multifaceted molecule, in innate immune responses against pathogens. Mediators Inflammation. 2017;2017:9247574.
   PubMed Web of Science ®Google Scholar
• Miller MC, Zheng Y, Zhou Y, et al. Galectin-3 binds selectively to the terminal, non-reducing end of beta(1–>4)-galactans, with overall affinity increasing with chain length. Glycobiology. 2019 Jan 1;29(1):74–84.
   PubMed Web of Science ®Google Scholar
• Miller MC, Ippel H, Suylen D, et al. Binding of polysaccharides to human galectin-3 at a noncanonical site in its carbohydrate recognition domain. Glycobiology. 2016 Jan;26(1):88–99.
   PubMed Web of Science ®Google Scholar
• Suthahar N, Meijers WC, Sillje HHW, et al. Galectin-3 activation and inhibition in heart failure and cardiovascular disease: an update. Theranostics. 2018;8(3):593–609.
   PubMed Web of Science ®Google Scholar
• Dumic J, Dabelic S, Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006 Apr;1760(4):616–635.
   PubMed Web of Science ®Google Scholar
• Dings RPM, Miller MC, Griffin RJ, et al. Galectins as molecular targets for therapeutic intervention. Int J Mol Sci. 2018 Mar 19;19(3):3.
   Web of Science ®Google Scholar
• Noureddin M, Sanyal AJ. Pathogenesis of NASH: the impact of multiple pathways. Curr Hepatol Rep. 2018 Dec;17(4):350–360.
   PubMedGoogle Scholar
• MacKinnon AC, Farnworth SL, Hodkinson PS, et al. Regulation of alternative macrophage activation by galectin-3. J Immunol. 2008 Feb 15;180(4):2650–2658.
   PubMed Web of Science ®Google Scholar
• Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5060–5065.
   PubMed Web of Science ®Google Scholar
• Nomoto K, Tsuneyama K, Abdel Aziz HO, et al. Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice. J Pathol. 2006 Dec;210(4):469–477.
   PubMed Web of Science ®Google Scholar
• Nakanishi Y, Tsuneyama K, Nomoto K, et al. Nonalcoholic steatohepatitis and hepatocellular carcinoma in galectin-3 knockout mice. Hepatol Res. 2008 Dec;38(12):1241–1251
   PubMed Web of Science ®Google Scholar
• Iacobini C, Menini S, Ricci C, et al. Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver. J Hepatol. 2011 May;54(5):975–983
   PubMed Web of Science ®Google Scholar
• Jeftic I, Jovicic N, Pantic J, et al. Galectin-3 ablation enhances liver steatosis, but attenuates inflammation and IL-33-dependent fibrosis in obesogenic mouse model of nonalcoholic steatohepatitis. Mol Med. 2015 May 22;21(1):453–465.
   PubMedGoogle Scholar
• Pejnovic N, Jeftic I, Jovicic N, et al. Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis. World J Gastroenterol. 2016 Nov 28;22(44):9706–9717.
   PubMed Web of Science ®Google Scholar
• Gao Y, Liu Y, Yang M, et al. IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis. Oncotarget. 2016 Jun 7;7(23):33649–33661.
   PubMedGoogle Scholar
• Vasseur P, Dion S, Filliol A, et al. Endogenous IL-33 has no effect on the progression of fibrosis during experimental steatohepatitis. Oncotarget. 2017 Jul 25;8(30):48563–48574.
   PubMedGoogle Scholar
• Li Z, Lv F, Dai C, et al. Activation of galectin-3 (LGALS3) transcription by injurious stimuli in the liver is commonly mediated by BRG1. Front Cell Dev Biol. 2019;7:310.
   PubMed Web of Science ®Google Scholar
• Traber PG, Zomer E, Avila MA. Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One. 2013;8(12):e83481.
   PubMed Web of Science ®Google Scholar
• Sanyal A, Lopez P, Lawitz E, et al. Tropifexor, a farnesoid X receptor agonist for the treatment of non-alcoholic steatohepatitis - Interim results based on baseline body mass index from first two parts of Phase 2b study FLIGHT-FXR. J Hepatol 2019;70:e796-e7. doi: 10.1016/S0618-8278(19)31587-7.
   Google Scholar
• Trauner M, Gulamhusein A, Hameed B, et al. The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis. Hepatology. 2019 Sep;70(3):788–801.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Rossi SJ, Paredes AH, et al. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis. Hepatology. 2020 Apr;71(4):1198–1212.
   PubMed Web of Science ®Google Scholar
• Charles ED, Neuschwander-Tetri BA, Pablo Frias J, et al. Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study. Obesity (Silver Spring). 2019 Jan;27(1):41–49.
   PubMed Web of Science ®Google Scholar
• Sanyal A, Charles ED, Neuschwander-Tetri BA, et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet. 2019 Dec 22;392(10165):2705–2717.
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016 Feb 13;387(10019):679–690.
   PubMed Web of Science ®Google Scholar
• Petit JM, Cercueil JP, Loffroy R, et al. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the lira-NAFLD study. J Clin Endocrinol Metab. 2017 Feb 1;102(2):407–415.
   PubMed Web of Science ®Google Scholar
• Loomba R, Kayali Z, Noureddin M, et al. GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology. 2018 Nov;155(5):1463–1473 e6.
   PubMed Web of Science ®Google Scholar
• Jones D, Boudes PF, Swain MG, et al. Seladelpar (MBX-8025), a selective PPAR-delta agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol. 2017 Oct;2(10):716–726.
   PubMed Web of Science ®Google Scholar
• Jain MR, Giri SR, Bhoi B, et al. Dual PPARalpha/gamma agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int. 2018 Jun;38(6):1084–1094.
   PubMed Web of Science ®Google Scholar
• Tacke F, Weiskirchen R. An update on the recent advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol. 2018 Nov;12(11):1143–1152.
   PubMed Web of Science ®Google Scholar
• Dibba P, Li AA, Perumpail BJ, et al. Emerging therapeutic targets and experimental drugs for the treatment of NAFLD. Diseases 2018 Sep 19;6(3):3.
   Google Scholar
• Noureddin M, Zhang A, Loomba R. Promising therapies for treatment of nonalcoholic steatohepatitis. Expert Opin Emerg Drugs. 2016 Sep;21(3):343–357.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Marri SR, Chalasani N, et al. Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis. Aliment Pharmacol Ther. 2016 Dec;44(11–12):1183–1198.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Abdelmalek MF, Garcia-Tsao G, et al. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology. 2020. Apr;1585:1334–1345. e5.
   PubMed Web of Science ®Google Scholar
• Sciacchitano S, Lavra L, Morgante A, et al. Galectin-3: one molecule for an alphabet of diseases, from A to Z. Int J Mol Sci. 2018 Jan 26;19(2):379
   Web of Science ®Google Scholar
• Dong R, Zhang M, Hu Q, et al. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). Int J Mol Med. 2018 Feb;41(2):599–614.
   PubMed Web of Science ®Google Scholar
• Wang L, Guo XL. Molecular regulation of galectin-3 expression and therapeutic implication in cancer progression. Biomed Pharmacother. 2016 Mar;78:165–171.
   PubMed Web of Science ®Google Scholar
• Ruvolo PP. Galectin 3 as a guardian of the tumor microenvironment. Biochim Biophys Acta. 2016 Mar;1863(3):427–437.
   PubMed Web of Science ®Google Scholar
• Thijssen VL, Heusschen R, Caers J, et al. Galectin expression in cancer diagnosis and prognosis: a systematic review. Biochim Biophys Acta. 2015 Apr;1855(2):235–247.
   PubMed Web of Science ®Google Scholar
• Xu WW, Zheng CC, Huang YN, et al. Synephrine hydrochloride suppresses esophageal cancer tumor growth and metastatic potential through inhibition of galectin-3-AKT/ERK signaling. J Agric Food Chem. 2018 Sep 5;66(35):9248–9258.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang P, Qin Y, et al. RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways. Oncogene. 2017 Mar 2;36(9):1297–1308.
   PubMed Web of Science ®Google Scholar
• Duckworth CA, Guimond SE, Sindrewicz P, et al. Chemically modified, non-anticoagulant heparin derivatives are potent galectin-3 binding inhibitors and inhibit circulating galectin-3-promoted metastasis. Oncotarget. 2015 Sep 15;6(27):23671–23687.
   PubMedGoogle Scholar
• Li HY, Yang S, Li JC, et al. Galectin 3 inhibition attenuates renal injury progression in cisplatin-induced nephrotoxicity. Biosci Rep. 2018 Dec 21;38(6):6.
   Google Scholar
• Martinez-Martinez E, Ibarrola J, Fernandez-Celis A, et al. Galectin-3 pharmacological inhibition attenuates early renal damage in spontaneously hypertensive rats. J Hypertens. 2018 Feb;36(2):368–376.
   PubMed Web of Science ®Google Scholar
• Ibarrola J, Arrieta V, Sadaba R, et al. Galectin-3 down-regulates antioxidant peroxiredoxin-4 in human cardiac fibroblasts: a new pathway to induce cardiac damage. Clin Sci (Lond). 2018 Jul 18;132(13):1471–1485.
   PubMed Web of Science ®Google Scholar
• Lok DJ, Van Der Meer P, De La Porte PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010 May;99(5):323–328.
   PubMed Web of Science ®Google Scholar
• Meijers WC, Januzzi JL, deFilippi C, et al. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. Am Heart J. 2014 Jun;167(6):853–60 e4.
   PubMed Web of Science ®Google Scholar
• Li J, Kuruba R, Wilson A, et al. Inhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand. PLoS One. 2010 Nov 11;5(11):e13955.
   PubMed Web of Science ®Google Scholar
• Mackinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012 Mar 1;185(5):537–546.
   PubMed Web of Science ®Google Scholar
• Cullinane AR, Yeager C, Dorward H, et al. Dysregulation of galectin-3. Implications for Hermansky-Pudlak syndrome pulmonary fibrosis. Am J Respir Cell Mol Biol. 2014 Mar;50(3):605–613.
   PubMed Web of Science ®Google Scholar
• Garcia-Revilla J, Deierborg T, Venero JL, et al. Hyperinflammation and fibrosis in severe COVID-19 patients: galectin-3, a target molecule to consider. Front Immunol. 2020;11:2069.
   PubMed Web of Science ®Google Scholar
• Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020 Jun;26(6):842–844.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Song WM, Andhey PS, et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease. Nat Med. 2020 Jan;26(1):131–142.
   PubMed Web of Science ®Google Scholar
• De Biasi S, Meschiari M, Gibellini L, et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat Commun. 2020 Jul 6;11(1):3434.
   PubMed Web of Science ®Google Scholar